This was the stock's second consecutive day of gains.

By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...

By Sneha S K and Sriparna Roy (Reuters) - The U.S. Food and Drug Administration said on Friday that it has approved an ...

We recently compiled a list of the Early Retirement Portfolio: 10 Stocks to Live Off Dividends. In this article, we are going ...

Bristol Myers Squibb Co. closed $4.40 below its 52-week high ($61.08), which the company achieved on November 11th.

Cancer-focused CytomX Therapeutics Inc. will lay off 40% of its workforce — about 50 employees — to help extend its cash into ...

Regeneron Pharmaceuticals is a strong investment with robust growth potential, fueled by FDA approvals and resilient market ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Failed to fetch dynamically imported module: https://uk.finance.yahoo.com/assets/_app/immutable/nodes/96.Cy8eSqq3.js ...

Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

Corporate borrowing surged to a record in 2024, up over a third from a year earlier as companies like AbbVie and Cisco looked ...

Texas Children’s Global HOPE and Baylor College of Medicine Global Health, with support from the Bristol Myers Squibb ...